Canadian investment bank AltaCorp Capital has published a research report explaining options for producing cannabinoids from sources beyond cannabis. Analyst and Managing Director David Kideckel, PhD, explained in “Synthetically-Derived Cannabinoids: The Next Generation of Cannabinoid Production” that synthetic and biosynthetic cannabinoid production have the potential to disrupt the cannabis industry supply chain. He details the benefits and disadvantages to these alternative production processes relative to plant-based extraction:
Kideckel expects that biosynthetic production could play an important role in creating cannabinoids for consumer and pharmaceutical products, though he doesn’t see synthetic methods entirely replacing plant-derived extraction, noting that it could be at least 18 months before they are commercially feasible. The report also lists several companies involved in these types of alternative production, some of which are publicly-traded.
To access the report, readers may request a copy from DKideckel@altacorpcapital.com
